Innovation Pharmaceuticals Inc (IPIX)

[runninggirl2016]

Biohedge you said "I know for a fact that CELG had no idea who Leo or Cellceutix was until late last year.

So who is not telling the truth here. You or Karin CA?
SO did Celgene know Leo and Cellceutix since 2012 or 2016?

I await your response...









At the 2012, J.P. Morgan Health Care Conference, Celgene's (CELG) CEO Bob Hugin heralded the company's psoriatic compound as a potential blockbuster that appeared destined to become a primary drug in the psoriatic area of dermatology for which it is in trials to address. However, several weeks later, the compound was reported as having difficulty in phase three clinicals and appeared to be unlikely to generate as promising of an advance as indicated. Expectations for Apremilast have been halved and Celgene now touts that its safety profile instead of its once speculated superior efficacy will be the agent of its market penetration. That said, the once diminished hopes for Apremilast have been bolstered by the latest announcement. However strong the recent announcement, Celgene quickly added a need for increased therapeutic advancement in treating the disease.

In an interview with KarinCA, Cellceutix (CTIX.OB) CEO, Leo Ehrlich, said that Celgene called Cellceutix and requested publicly available documents from the company. Cellceutix's two primary compounds are Kevetrin and Prurisol (KM 133).